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Abstract
Introduction: Autoantibodies against citrullinated peptides/proteins (ACPA) are found in approximately 75% of the
sera of patients with rheumatoid arthritis (RA). The RA-specific ACPA are frequently present prior to disease onset
and their presence associates with a more erosive disease course. ACPA can therefore be used to aid the diagnosis
and prognosis of RA. Recently, it became clear that ACPA are very heterogeneous, both in an individual patient and
among different patients. The aim of this study was to investigate whether clinically meaningful ACPA profiles exist
in early RA patients.
Methods: Twenty citrullinated peptides and the corresponding non-citrullinated control peptides were immobilized
on microarray sensor chips. Sera from 374 early arthritis patients were analyzed by surface plasmon resonance
imaging (iSPR) of biomolecular interactions on the sensor chip.
Results: Cluster analysis of the reactivities with the citrullinated peptides, after subtraction of the reactivities with
the corresponding control peptides confirmed the heterogeneity of the ACPA response in RA and revealed 12
distinct ACPA profiles. The association of the 5 most frequent profiles with clinical features at diagnosis and during
the disease course was examined, showing no statistically significant associations.
Conclusions: Compared to the detection of ACPA in RA sera by CCP-based assays, ACPA profiling in early arthritis
patients did not reveal associations with disease activity and progression scores.
Introduction
Autoantibodies against citrullinated proteins (ACPAs) are
specifically found in approximately 75% of rheumatoid
arthritis (RA) patients [1]. Citrullination is the posttransla-
tional conversion of peptidylarginine into peptidylcit-
rulline, which is catalyzed by peptidylarginine deiminase
in a calcium-dependent manner [2]. Accumulating evi-
dence suggests that citrullinated proteins and ACPAs are
directly involved in the pathophysiology of RA. Several
citrullinated antigens (for example, fibrinogen, α-enolase,
vimentin, collagen type II and fibronectin) have been iden-
tified in the inflamed joints of RA patients [3-9].
Citrullinated autoepitopes of these proteins provide the
opportunity to investigate the ACPA response to genuine
autoantigens and to assess the production of autoanti-
bodies to these epitopes early in disease.
The diagnosis of RA relies in part on the detection of
ACPA, for example, by the most commonly applied cyc-
lic citrullinated peptide 2 (CCP2) test [10]. It has been
demonstrated that ACPAs are already present prior to
disease onset and that they are associated with a more
severe course of RA [11-13]. Although just about all
ACPAs are reactive in the CCP2 test, diverse reactivity is
observed when other citrullinated molecules are used,
for example, peptides derived from fibrinogen and
vimentin [14]. This indicates that the ACPA response in
RA is heterogeneous, with diverse patterns of reactivity
to distinct citrullinated epitopes. Currently, RA patients
are classified into two distinct groups: anti-CCP2-posi-
tive and anti-CCP2-negative. It remains to be investi-
gated whether the ACPA fine specificity may improve
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diagnosis and/or prognosis [15,16]. Because the ACPA
response is very heterogeneous and differs among indi-
vidual RA patients, identifying ACPA profiles and ana-
lyzing their association with clinical features, rather than
looking at the ACPA-positive RA patients as one group,
may facilitate the subclassification of patients and may
aid the development of “patient-tailored” therapies in
the future. It is interesting to note that low and inter-
mediate pretreatment levels of ACPA appear to be asso-
ciated with a more favorable response to methotrexate
treatment in recent onset anti-CCP-positive arthritis,
whereas high levels are associated with an insufficient
response [17].
ACPA profiles can be determined most efficiently by
using multiplex assays, in which multiple citrullinated
antigens are tested simultaneously [18-21]. An example
of such a multiplex assay is microarray surface plasmon
resonance imaging (iSPR), which is a label-free method
used to detect biomolecular interactions in real time.
The fully automated iSPR analysis requires only a min-
imal amount of serum, and the microarray-containing
sensor chips can be regenerated and used repeatedly.
The use of iSPR for monitoring autoantibody binding to
different citrullinated targets was first described by
Lokate and coworkers [22], and later citrullinated B-cell
epitopes in fibrinogen were successfully mapped with
the use of this technology [23]. A recently introduced
continuous flow spotting system to generate the iSPR
microarrays not only improved the robustness and re-
producibility of the arrays but also allowed much higher
spotting volumes and an increased number of spots per
array.
In our present study, we applied an iSPR microarray
to identify ACPA profiles in early arthritis patients using
a microarray containing 20 citrullinated peptides, as well
as their noncitrullinated counterparts, and compared
these profiles with clinical features of the patients.
Methods
Patient information
Early arthritis sera (n = 374) were collected at the De-
partment of Rheumatology of the Leiden University
Medical Center (Leiden, The Netherlands) from the Lei-
den Early Arthritis Clinic. All patients fulfilled the
American Rheumatism Association 1987 revised criteria
for the classification of RA within one year of follow-up
[24]. The Leiden Early Arthritis Clinic is an inception
cohort of patients with recent-onset arthritis (symptom
duration less than two years) that was started at the De-
partment of Rheumatology of the Leiden University
Medical Center in 1993 and was described in detail pre-
viously [25].
At the time of inclusion, patients were asked about
their joint symptoms and underwent a physical
examination. At baseline and at the yearly follow-up
visits, blood samples were taken for routine diagnostic
laboratory screening and serum was stored at −70°C.
Written informed consent was obtained from all par-
ticipants. The study was approved by the local medical
ethics committee of the Leiden University Medical
Center.
Sera from healthy individuals (n = 10) were collected at
the Sanquin Blood Bank in Nijmegen, The Netherlands.
Sera were stored at −70°C until use. Total immunoglobu-
lin G anti-CCP2 antibodies in RA sera were measured
using the Immunoscan CCPlus enzyme-linked immuno-
sorbent assay (ELISA) kit (Euro Diagnostica AB, Malmö,
Sweden). Samples with a value greater than 25 U/ml were
considered positive.
Preparation of the microarrays and surface plasmon
resonance imaging analyses
Peptides (Table 1) were synthesized by performing a
solid-phase procedure using 9-fluorenylmethyloxycar-
bonyl chemistry as described previously [26]. The pep-
tides were at least 90% pure, as deduced from their
elution pattern on reverse-phase high-performance
liquid chromatography. Biotinylated peptides were
immobilized on an iSPR chip containing a streptavidin
hydrogel linked to a gold layer on a glass surface (Ssens
BV, Enschede, The Netherlands) (Additional file 1:
Figure S1A). In short, immobilization of the peptides
was initiated by spotting the peptides on the surface of
the sensor discs using a continuous flow microspotter
(Watsatch Microfluidics, Salt Lake City, UT, USA) for
one hour to generate a 48-spot microarray (Additional
file 1: Figure S1B) containing 48 spots of approximately
0.5 mm2 each (Additional file 1: Figure S1C).
Prior to use, sera were diluted 50-fold in phosphate-
buffered saline (PBS) with 0.075% Tween 80. Incubation,
washing and regeneration were performed in an auto-
mated way using liquid-handling procedures in a com-
prehensive surface plasmon resonance imaging system
for multiplexing 96 biomolecular interactions (IBIS-
MX96, IBIS Technologies, Enschede, The Netherlands).
Using the IBIS-MX96 system, a diluted serum sample
plug of 80 μl was injected and 20 μl were guided back-
ward and forward over the microarray in a flow cell at a
speed of 30 μl/s to allow autoantibody binding to the
immobilized peptides for 40 minutes. The serum sample
plug was flanked by two air plugs to prevent the diffu-
sion of serum components into the buffer. Between the
association phase and the regeneration phase, the flow
cell was rinsed with PBS with 0.075% Tween 80 for eight
minutes. The array was regenerated twice by two con-
secutive injections of 80 μl of 10 mM glycine∙HCl, pH
2.5, for 30 seconds.
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Table 1 Peptide sets immobilized on the microarrays for surface plasmon resonance imaging analysisa
Set Origin Peptide sequence Position of citrulline residuesb
1 A α-enolase (cyclic) CKIHAREIFDSRGNPTVECZO
B CKIHAXEIFDSXGNPTVECZO 9, 15
2 A β-actin MKILTERGYSFTTAEREIVRDIKEKLZO
B MKILTEXGYSFTTAEXEIVXDIKEKLZO 196, 206, 210
3 A CCP2-like (cyclic) c
B n.r.
4 A Collagen type II GLPGVKGHRGYPGLDGAZO
B GLPGVKGHXGYPGLDGAZO 290
5 A Fibrinogen FLAEGGGVRGPRVVERHZO
B FLAEGGGVXGPRVVERHZO α35d
6 A Fibrinogen TSSTSYNRGDSTFZO
B TSSTSYNXGDSTFZO α591d
7 A Fibrinogen NEEGFFSARGHRPLDKKZO
B NEEGFFSAXGHRPLDKKZO β44e
8 A Fibrinogen EEAPSLRPAPPPISGGGYRARPAKAAAZO
B EEAPSLXPAPPPISGGGYXAXPAKAAAZO β60, 72, 74e
9 A Fibronectin LTVGLTRRGQPRQYZO
B LTVGLTXXGQPRQYZO 1,035, 1,036
10 A Fibronectin YNQYSQRYHQRTNZO
B YNQYSQXYHQRTNZO 2356
11 A Filaggrin (cfc1; cyclic) HQCESTRGRSRGRCGRSGSZO f
B HQCESTXGRSRGRCGRSGSZO
12 A MNDA KLTSEARGRIPVAQKZO
B KLTSEAXGXIPVAQKZO 127, 129
13 A Peptide library c
B n.r.
14 A Peptide library c
B n.r.
15 A Peptide library c
B n.r.
16 A Peptide library c
B n.r.
17 A Vimentin MSTRSVSSSSYRRMFGGPZO
B MSTXSVSSSSYXXMFGGPZO 4, 12, 13
18 A Vimentin GVYATRSSAVRLRSSVPGZO
B GVYATXSSAVXLXSSVPGZO 64, 69, 71
19 A Vimentin LTAALRDVRQQYESZO
B LTAALXDVXQQYESZO 270, 273
20 A Vimentin SLNLRETNLDSLPLVDZO
B SLNLXETNLDSLPLVDZO 424
aCCP2, cyclic citrullinated peptide 2; MNDA, myeloid cell nuclear differentiation antigen; n.r., not relevant; O, biotinylated lysine; X, citrulline; Z, aminohexanoic
acid. bAmino acid position in the corresponding polypeptide relative to the N-terminal methionine of the primary translation product. cSequence is defined in
patent EP2071335. dα-Chain of fibrinogen. eβ-Chain of fibrinogen. fDerived from sequence presented in [27].
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A mixture of two monoclonal ACPAs (10 μg/ml of
each antibody; Modiquest BV, Oss, The Netherlands)
and serum from an anti-CCP2-positive RA serum (50-
fold dilution; Radboud University Medical Centre Nij-
megen) as a control to verify successful immobilization
and as a standard for different microarrays. To obtain
quantitative results for antibody binding to the peptides,
the data were analyzed using SPRint software (IBIS
Technologies, Enschede, The Netherlands).
Data analysis
Hierarchical clustering software Cluster 3.0 was used to
identify ACPA profiles, and the results were displayed
using Java TreeView software (Stanford University, Stan-
ford, CA, USA).
The association of the different clusters of patients with
categorical baseline characteristics (for example, gender,
CCP2) was studied using Pearson’s χ2 test. The independ-
ent samples Kruskal-Wallis test was performed to address
associations with clinical phenotype (Disease Activity
Score, Visual Analogue Scale (VAS) score, swollen joint
counts, tender joint count (Ritchie index), erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)).
Furthermore, the association of the different clusters
and joint damage over time was studied. Radiographs of
hands and feet, taken at baseline and yearly thereafter
during seven years of follow-up, were assessed according
to the Sharp/van der Heijde score (SHS) with known
time order by an experienced reader who was blinded to
any clinical information. The within-reader intraclass
correlation coefficient was 0.91. This method takes ad-
vantage of the longitudinal, repetitive character of the
data and does not exclude patients with incomplete
follow-up data, thus avoiding selection bias.
In a multivariate normal regression model with radio-
logical score used as the response variable, the effect of
time was entered as a factor to fit the nonlinear slope of
joint destruction. The components were entered with an
interaction term with time used as a continuous variable
to test the effect of the components over time. Age, gen-
der and inclusion period (a proxy for treatment strategy)
were entered into the model to correct for possible
confounding effects. Analyses were performed using SPSS
version 17.0 software (SPSS, Inc, Chicago, IL, USA), and P
values below 0.05 were considered statistically significant.
Results
Autoantibody detection in patient sera by microarray
surface plasmon resonance imaging
An overview of the method used in the present study is
shown in Figure 1. The use of iSPR to study antibody-
antigen binding has been described previously [22,23].
Since then, several adjustments have been made to the sys-
tem, the most important of which is the immobilization of
peptides on the microarrays. To avoid flowing out of the
small droplets spotted on the surface, ligands (for example,
peptides) are now placed on a sensor chip by continuous
flow microspotting, in which a 48-channel printhead
makes direct contact with the surface of the sensor chip.
Each peptide solution is pumped back and forth along a
defined spotting area of the chip for one hour. Further-
more, streptavidin-coated hydrogel sensor chips were used
to immobilize C-terminal biotinylated peptides, which not
only results in a similar mode of presentation of all pep-
tides but also is less laborious. Other adjustments concern
software updates improving data analysis.
Because the streptavidin-coated sensor chips were not
used before for autoantibody detection by microarray iSPR
and the streptavidin-biotin interaction is not covalent, it
was necessary to determine the effects of acid-induced
microarray regeneration. A standard microarray sensor
chip was consecutively incubated 30 times with different
analytes, with a regeneration step between each of the
serum incubations. The results showed that the
microarrays could be reused more than 30 times without a
major reduction in resonance angle shift. In addition, the
reproducibility of the microarray analyses was demon-
strated by the inclusion of patient serum reactive with
multiple citrullinated peptides and a mixture of monoclo-
nal antibodies to citrullinated proteins (Additional file 1:
Figure S2).
Peptide microarrays for multiplexed detection of
autoantibodies against citrullinated protein
Over the past decade, several citrullinated autoantigens
targeted by ACPA have been identified (fibrinogen,
vimentin, α-enolase, fibronectin and collagen type II)
[3-7,9]. In initial iSPR experiments, we have explored
the suitability of 31 peptide sets (citrulline-containing
and corresponding arginine- or norleucine-containing
peptides) derived from several citrullinated autoantigens.
This research led to the selection of 20 peptide sets
(Table 1) derived from fibrinogen (four sets), fibronectin
(two sets), collagen type II (one set), vimentin (four sets),
α-enolase (one set), β-actin (one set), myeloid nuclear
differentiation antigen (one set) and filaggrin (one set)
or isolated from randomized peptide libraries (five sets)
for the generation of the standard microarray. The
remaining eight spots were reserved for several highly
reactive citrullinated peptides, which served as quality
controls in the microarrays. On the basis of the results
obtained with sera from healthy controls, a cutoff value
of 10 mdeg was chosen.
Detection of autoantibodies against citrullinated protein
detection by microarray surface plasmon resonance imaging
Serum samples from 374 early arthritis patients were an-
alyzed with iSPR using the synthetic peptide microarrays
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described above. A total of 187 of these patients were
anti-CCP2-positive, and 187 were anti-CCP2-negative at
baseline, as revealed in anti-CCP2 ELISA tests. As ex-
pected, various reactivity patterns were observed for
these sera, and anti-CCP2-positive sera generally showed
more reactivity with citrullinated peptides than with the
corresponding control peptides. In addition, the iSPR
data emphasize the heterogeneity of the ACPA response
in the anti-CCP2-positive patients (Figure 2).
Eleven (6%) of the anti-CCP2-negative sera recognized
at least one citrullinated peptide. Eight of these sera rec-
ognized one citrullinated peptide, two sera were reactive
with two citrullinated peptides and one serum recog-
nized four citrullinated peptides (Figure 3).
During the analysis, cycles of each sensor chip a mix-
ture of two monoclonal ACPAs and a highly reactive RA
serum were used as positive controls to confirm efficient
peptide immobilization (Figure 2).
Autoantibody against citrullinated protein profiling
To identify the presence of common reactivity patterns in
the data set, obtained after subtracting the reactivities
lobserved with the control peptides from those of the
corresponding citrullinated peptides, cluster analysis was
performed. On the basis of the results (Figure 3), we de-
fined 12 different clusters of patients (A through L), some
of which comprise only a limited number of patients. Re-
markably, one of these clusters (F) contains both anti-
CCP2-positive and anti-CCP2-negative patients. The
results of principal component analysis (Additional file 1)
support the differentiation in ACPA profile clusters (A
through L) identified with hierarchical clustering software
Cluster 3.0 (Additional file 1: Figure S3).
Five clusters (C, D, E, F and H), each consisting of more
than 15 patients, were analyzed for associations with
serological, genetic and clinical features. From C to H,
the percentage of anti-CCP2-positive and RF-positive
sera, the mean ACPA levels, the percentage of the differ-
ent ACPA isotypes and the frequency of HLA-DRB1
shared epitope (SE) positivity gradually decreased (Table 2
and Additional file 1: Table S1). Similarly, the mean
number of citrullinated peptides recognized decreased
(Table 2). The different clusters displayed significant dif-
ferences in mean ACPA levels, ACPA status and the pres-
ence of HLA-DRB1 SE alleles.
No associations were observed between different
ACPA profiles and several disease characteristics at
baseline (gender, Ritchie index score, number of swollen
Figure 1 Schematic overview of autoantibody detection by microarray surface plasmon resonance imaging. (A) Biotinylated peptides are
immobilized on a sensor chip which contains a gold surface with a streptavidin hydrogel on top. Each peptide (48 in total) is pumped back and
forth along a specific position of the chip for one hour. This leads to a 48-spot microarray, in which each spot contains a different peptide. (B)
Interactions of serum antibodies with peptides on the 48-spot microarray are detected by surface plasmon resonance imaging (iSPR). The
incident light is reflected at the sensor chip surface and detected by a charge-coupled device (CCD) camera. (C) At a certain incidence angle, the
amount of reflected light will be at a minimum. The binding of an antibody leads to a mass change at the surface and results in a shift in the
resonance angle. The resonance angle is plotted against time to generate a sensorgram.
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joints, CRP level, ESR and pain sensation measured by
VAS score (Table 2 and Additional file 1: Table S1).
Radiological progression over seven years, studied on
the basis of SHS, also was not associated with the differ-
ent ACPA profiles. As expected, the cluster of patients
with the highest percentage ACPA-positive patients
displayed more joint damage than the ACPA-negative
cluster. After stratification for ACPA status, however, no
significant differences between the clusters remained.
Discussion
In the present study, microarray iSPR analysis was used to
identify ACPA fine-specificity profiles. Twenty peptide sets
derived from eight different proteins and peptides from
peptide library screenings were used to study and deter-
mine the ACPA profiles. Twelve distinct ACPA profiles
were identified in three hundred seventy-four early arthritis
patients. The data confirm the heterogeneity of the ACPA
response in RA patients. Sera from patients with the ACPA
profile with the highest percentage anti-CCP2 positivity
also showed the highest ACPA levels, as well as the highest
number of citrullinated peptides recognized, and were from
patients with the highest percentage of SE alleles. No asso-
ciation with smoking was observed (Table 2).
Associations of ACPA profiles with clinical features
might be helpful in determining patients’ prognosis and
the development of “tailor-made” treatment, as has been
demonstrated for anti-CCP2 positivity in general, which
is associated with more erosive disease and for which
the effectiveness of early treatment (for example, by
combined drug therapy) to prevent progression of joint
destruction has been demonstrated [28]. Our analyses of
the five most frequently observed profiles in the early
arthritis cohort did not demonstrate associations with
disease activity or erosion levels.
The reactivity to multiple citrullinated antigens has been
addressed in several studies, in most cases on the basis of
ELISA [29-32]. In agreement with our data, in these prior
studies, no association with clinical characteristics was ob-
served [29,33]. It is still too early to conclude that ACPA
profiling is clinically meaningless. The number of sera that
have been analyzed is still relatively low and came from a
limited number of cohorts. Larger numbers of samples,
from independent cohorts and from distinct stages of dis-
ease development, need to be analyzed to validate the
clustering obtained with the early arthritis sera, to gener-
ate more reliable data on correlations with clinical fea-
tures and to address associations with the minor profiles.
Figure 2 Detection of autoantibodies against citrullinated protein in anti-cyclic citrullinated peptide 2-positive early arthritis sera by
microarray surface plasmon resonance imaging. Sensorgrams for the binding of 20 anti-CCP2-positive early arthritis sera to four peptide sets are
shown. The different citrullinated peptides are depicted in different shades of red, and the arginine control peptides are shown in different shades of
green. The different colors the four different citrullinated peptides illustrate the data listed in Table 1. Widely reactive autoantibodies against
citrullinated protein (ACPA)-positive serum from a rheumatoid arthritis patient (X) and a mixture of two monoclonal ACPAs (Y) were used as controls.
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Besides microarray iSPR, several alternative multiplex
systems have been developed to profile biomolecular
markers in RA. These include systems for multiple
serum biomarkers (for example, CRP, interleukin 6) [34],
multiple gene expression profiling [35] and the detection
of multiple cytokines to predict disease development
and the response to therapy [36-38]. In addition, several
systems for autoantibody profiling have been developed,
most of which are focused on multiplexed ACPA detec-
tion [19-21,38]. A comparison of the citrullinated anti-
gens used in these multiplex assays with the molecules
used in the current study is given in Additional file 1:
Table S2.
One of the first multiplex ACPA profiling assays, pro-
tein/peptide microarrays on which antibody binding
was detected by fluorescent secondary antibodies, was
Figure 3 Clustering of early arthritis patient sera based upon microarray surface plasmon resonance imaging data. Microarray surface
plasmon resonance imaging data for 374 early arthritis patient sera were subjected to cluster analysis using Cluster 3.0 software. The results were
used to generate a heat map, with the results for the individual peptides given in rows (peptide numbers indicated on the right) and those for
the patients given in columns. (A) through (L) On the basis of the dendrograms, 12 autoantibodies against citrullinated protein profiles were
defined. Below the heat map, the anti-cyclic citrullinated peptide 2 (CCP2) reactivity is shown: anti-CCP2-positive is shown in different shades of
brown and orange, and anti-CCP2-negative is shown in blue. Fib: fibrinogen; FN: fibronectin; Pep. Lib.: peptide library; MNDA: myeloid cell nuclear
differentiation antigen; Vim: vimentin.
Table 2 Autoantibody and disease features of patients with the five major autoantibodies against citrullinated protein
profilesa
Group n Anti-CCP2+b
(%)
RF+
(%)
Mean ACPA level
(U/ml)
Mean number of citrullinated antigens
recognized (range)c,d
(Ex-) smokers
(%)e
SE+f
(%)d
VAS
mediang
C 15 100 93 4630 6 (1 to 16) 38 93 34
D 83 88 87 1317 3 (1 to 13) 59 80 35
E 30 87 87 861 2 (0 to 5) 66 70 34
F 198 31 45 137 0 (0 to 4) 49 53 40
H 17 0 29 14 0 (0 to 1) 60 29 50
aACPA: anticitrullinated protein antibody; CCP2: cyclic citrullinated peptide 2; RF: rheumatoid factor; SE: shared epitope; VAS: Visual Analogue Scale score.
bMeasured using the anti-CCP2 test (CCPlus Immunoscan assay). cReactivity is based upon cutoff values determined with reactivity of healthy individuals with
surface plasmon resonance imaging. dP-value < 0.01. eP-value = 0.278. fAt least one SE allele. gP-value = 0.958. Group differences were tested using the
Kruskal-Wallis test or Pearson’s χ2 test.
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described by Hueber and coworkers [38]. The results
showed that patients whose sera were predominantly re-
active with citrullinated antigens carry two SE alleles and/
or reported increased Health Assessment Questionnaire
(HAQ) disability scores. Using our microarrays, we ob-
served similar correlations with SE status, as noted above.
Although HAQ scores (which include aspects of disability,
pain, medication effects, cost of care and mortality) were
not assessed in our study, the VAS scores (which register
only pain sensation) were not significantly different be-
tween the patients with the five different ACPA profiles
analyzed.
A more reproducible and automated variant of this
system was reported by Chandra and coworkers [20]. In
addition, in this system, fluorescently labeled antibodies
were used to detect autoantibodies as well as cytokines
bound on the microarrays. Cluster analysis of a data set
obtained with this system confirmed the association of
ACPA with SE-positive RA patients. Advantages of this
multiplex assay are its reproducibility and the fact that
RA patients can be clearly distinguished from control in-
dividuals. Disadvantages are that the number of different
markers (ten) that can be measured simultaneously is
limited and that the chip can be used only once.
Sokolove and colleagues developed a novel multiplex
system using a bead-based assay in which 20 target anti-
gens, including 3 arginine control proteins, 3 (in vitro)
citrullinated proteins and 14 citrullinated peptides can
be measured simultaneously [21]. They reported in-
creased autoantibody reactivity over time as individuals
approached the development of clinical RA. In agree-
ment with previously published ELISA data [39], they
observed a correlation between the increasing number
of ACPA subtypes and elevation of anti-CCP2 titers.
This finding is similar to our observations that patients
with the ACPA profile with the highest mean ACPA
levels (C) are also reactive with the highest number of
citrullinated antigens (Table 2).
Recently, another microarray-based multiplex system
for the detection of autoantibodies against citrullinated
peptides was introduced [19]. In this system, 12 peptide
sets (partially similar to the peptides used in our study; see
Additional file 1: Table S3) were used as target antigens. A
good correlation with results obtained by ELISA was ob-
served. An advantage of the latter method is the ability to
measure reactivities with 170 antigens simultaneously.
This system was successfully used to study antibodies
against citrullinated peptides in individuals prior to RA
development [40]. In agreement with previously published
data [39,41], the results of this study showed that the
ACPA response is initially restricted but expands over
time with increasing levels toward disease onset. It is im-
portant to note that, in all these systems, labeled anti-
bodies are needed for the detection of bound antibodies.
Conclusions
Microarray iSPR analysis is the only label-free, real-time
detection system for autoantibodies described so far.
The ability to regenerate the microarrays and to analyze
more than 30 patient sera consecutively in a fully auto-
mated fashion on a single array makes this system
unique among the various multiplex systems that have
been developed. Moreover, only very small volumes of
serum are required to measure reactivity with multiple
target molecules simultaneously.
ACPA profiling using microarrays containing 20 pep-
tide sets derived from 8 different proteins and peptides
derived from peptide library screenings allowed the
identification of 12 distinct ACPA profiles in 374 early
arthritis patients. These data confirm the heterogeneity
of the ACPA response in RA patients. ACPA profiling in
these early arthritis patients did not reveal associations
with disease activity and progression scores.
We conclude that microarray iSPR represents a suitable
system for multiplexed ACPA detection in patient sera
and that more analyses have to be performed to assess the
predictive and/or prognostic value of ACPA profiling.
Additional file
Additional file 1: Supplementary Materials and Methods;
Supplementary Tables S1 and S2; Supplementary Figures S1–S3.
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